Eli Lilly and Company (LLY) Shares Bought by Bank of Nova Scotia
Bank of Nova Scotia increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 918.6% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 224,831 shares of the company’s stock after buying an additional 202,758 shares during the period. Bank of Nova Scotia’s holdings in Eli Lilly and were worth $18,910,000 as of its most recent filing with the SEC.
Other hedge funds also recently made changes to their positions in the company. Heritage Trust Co acquired a new stake in Eli Lilly and in the 1st quarter worth about $135,000. Point72 Asia Hong Kong Ltd raised its stake in Eli Lilly and by 237.4% in the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after purchasing an additional 1,239 shares in the last quarter. Penserra Capital Management LLC raised its stake in Eli Lilly and by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after purchasing an additional 176 shares in the last quarter. Sandy Spring Bank raised its stake in Eli Lilly and by 51.8% in the 1st quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock worth $185,000 after purchasing an additional 750 shares in the last quarter. Finally, Coldstream Capital Management Inc. acquired a new stake in Eli Lilly and in the 1st quarter worth about $200,000. 75.77% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Eli Lilly and Company (LLY) Shares Bought by Bank of Nova Scotia” was first published by Daily Political and is owned by of Daily Political. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/09/12/eli-lilly-and-company-lly-shares-bought-by-bank-of-nova-scotia.html.
Eli Lilly and Company (NYSE:LLY) traded down 0.38% during midday trading on Tuesday, hitting $82.32. 1,043,737 shares of the stock were exchanged. The stock has a market cap of $86.85 billion, a PE ratio of 35.62 and a beta of 0.34. The company’s 50 day moving average is $80.88 and its 200-day moving average is $82.05. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $86.72.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping the consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.86 earnings per share. On average, analysts expect that Eli Lilly and Company will post $4.16 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.52%. The ex-dividend date was Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is currently 90.04%.
LLY has been the subject of several analyst reports. TheStreet upgraded shares of Eli Lilly and from a “c+” rating to a “b+” rating in a research note on Tuesday, July 25th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $92.00 price objective on shares of Eli Lilly and in a research note on Tuesday, May 16th. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective for the company in a research note on Monday, July 17th. Jefferies Group LLC reiterated a “buy” rating and issued a $96.00 price objective (up previously from $93.00) on shares of Eli Lilly and in a research note on Thursday, July 13th. Finally, Citigroup Inc. reiterated a “buy” rating and issued a $100.00 price objective on shares of Eli Lilly and in a research note on Tuesday, July 4th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $88.07.
In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $84.43, for a total value of $17,730,300.00. Following the sale, the insider now owns 124,265,804 shares in the company, valued at $10,491,761,831.72. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last quarter, insiders sold 825,000 shares of company stock worth $68,456,650. 0.20% of the stock is currently owned by company insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.